

Advances in Neuroendocrine Neoplasms

Guest Editor:

Prof. Dr. Costanza Chiapponi

1. Department of General, Visceral, Cancer and Transplant Surgery, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany
2. Department of General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal, Weyertal 76, 50937 Cologne, Germany

Deadline for manuscript submissions:

closed (15 September 2024)


Message from the Guest Editor

Dear Colleagues,

The heterogeneity of neuroendocrine neoplasms (NENs), reflected in their various levels of clinical aggressiveness and responses to therapy, has been gradually unraveled over the last several decades. Thanks to the growing number of studies and research activity, there have been several updates to our knowledge of the landscape of their diagnostic and treatment options. Novel targeted drugs, imaging tools, and radionuclides for peptide receptor radionuclide therapy (PRRT) have been introduced, leading to numerous new guidelines and guidance papers. There is a mounting awareness of the role of precision medicine, particularly in this field. The purpose of the present Special Issue is to collect original research, expert opinions, and reviews building on basic, translational, and clinical aspects of these advances and shedding light on possible future directions.

Prof. Dr. Costanza Chiapponi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)